β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study.
Sibylle de GermayCécile ConteOlivier RascolJean-Louis MontastrucMaryse Lapeyre-MestrePublished in: CNS drugs (2021)
This study did not identify an increased risk of PD occurrence after β-antagonist exposure, except for propranolol (potential protopathic bias). The discordant results observed with β-agonists in patients with or without diabetes deserve further exploration of the influence of diabetic comorbidity on PD occurrence and evolution.